Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | CD4 |
Clinical data | |
Other names | BT-061 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
![]() ![]() |
Tregalizumab is an immunomodulator.[1] It is also known as BT-061. Tregalizumab binds to domain 2 of CD4,[2] and activates Regulatory T cells (Tregs).[3]